We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CERC-002

News List

FDA grants fast track designation to Cerecor’s Covid-19 treatment pharmaceutical-technology
May 12, 2021
The US Food and Drug Administration (FDA) has granted fast track designation to Cerecor’s fully human monoclonal antibody (mAb), CERC-002, for treating hospitalised Covid-19 patients.
Cerecor’s antibody reduces respiratory failure in Covid-19 ARDS trial pharmaceutical-technology
March 03, 2021
Cerecor has reported that final efficacy data from Phase II trial of human anti-LIGHT (TNFSF14) monoclonal antibody, CERC-002, in hospitalised patients with Covid-19 linked pneumonia and mild-to-moderate acute respiratory distress syndrome (ARDS) met ...